Unnatural Products Announces BridgeBio Exercises Option To License Macrocyclic Peptide Candidates Discovered Using UNP's AI-Enabled Massively Parallel Chemistry Platform
Mizuho Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating
BridgeBio Pharma Receives Buy Rating Following Attruby's FDA Approval and Strategic Milestones
Trending Stocks Today | Ambarella Shoots up 24.58% Post-Market
BridgeBio Selects PANTHERx Rare Specialty Pharmacy for Distribution of Attruby (Acoramidis)
BridgeBio Stock Up on FDA Approval of Cardiovascular Drug
105069706 : Fifty rides in just one day.
leo1212 : will it?